Information Provided By:
Fly News Breaks for July 29, 2019
CHE
Jul 29, 2019 | 09:35 EDT
RBC Capital analyst Frank Morgan raised his price target on Chemed to $405 after its "strong" Q2 results driven by another quarter of growth at VITAS Healthcare with higher admissions. The analyst keeps his Sector Perform rating but contends that the management may issue a "strong" guidance raise next month if CMS finalizes its 2020 rate update and rebasing as proposed.
News For CHE From the Last 2 Days
CHE
CHE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.